New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Sensoril studied in 5 human trials

Sensoril studied in 5 human trials

All five studies on the top-selling patented Ashwagandha extract in North America were randomized, double-blind, placebo-controlled trials.

Natreon Inc. and NutraGenesis LLC are pleased to announce that Sensoril®, the biggest-selling patented extract of Ashwagandha sold in North America is the subject of five new human clinical trials. The studies are wide ranging in their assessment of the comprehensive health benefits of Sensoril. All five studies were randomized, double-blind, placebo-controlled trials.

The first study was conducted by researchers at the University of Pittsburgh and assessed Sensoril’s ability to support memory and mental cognition in a clinical setting with patients experiencing short term memory and focus issues.

The second double-blind, placebo-controlled study was conducted in a multi-center clinical setting and evaluated Sensoril for anxiety.

An additional study investigated the effects of Sensoril on endothelial function, both when taken alone and in combination with Capros®, a patented Indian Gooseberry extract. Subjects in this study were evaluated for lipid profile, inflammation (CRP reduction), glutathione increase, nitric oxide increase and blood sugar balance. The positive control in the study was a popular statin drug which has recently gone generic. The final two studies assessed cardiovascular changes in healthy subjects under cold stress and mental stress conditions.

“We are delighted with the results of these five studies, which will be published soon, and we look forward to sharing them in the near future with our customers and the industry”, says Dr. Sanni Raju, CEO and chairman of the board of Natreon Inc. “Our commitment to building the research and intellectual property platform for Sensoril on behalf of our customers and partners has and always will be our first priority,” Dr. Raju added. “Natreon’s intellectual property around Ashwagandha is extensive, involving several U.S. and international patents which cover extracts produced from root only with a 3% minimum withanolide content and higher, and extracts produced from root and leaf with a minimum 8% withanolide content and higher. We at Natreon take our investment into the intellectual property and scientific research for our ingredients very seriously and we actively enforce our patent rights.”

Suzanne McNeary, president of NutraGenesis, LLC, the exclusive licensee for Sensoril in North America, added, “the results of these new studies further solidify Sensoril’s superiority in the Ashwagandha marketplace. As the most concentrated, multi-patented, truly full-spectrum Ashwagandha extract with over a decade of safe and efficacious use in the industry, it’s the reason that Sensoril is the number one choice in Ashwagandha extracts of fine dietary supplement brands around the world”.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.